A golden opportunity for Pristine Capital to make a real estate acquisitions. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksVerici Dx Regulatory News (VRCI)

Share Price Information for Verici Dx (VRCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.50
Bid: 4.25
Ask: 4.75
Change: -0.75 (-14.29%)
Spread: 0.50 (11.765%)
Open: 5.25
High: 5.25
Low: 4.125
Prev. Close: 5.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Result of Retail Offer

14 Feb 2024 07:00

RNS Number : 0458D
Verici Dx PLC
14 February 2024
 

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN (TOGETHER THIS "ANNOUNCEMENT") IS RESTRICTED AND IS NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN, INTO OR FROM THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS, ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA (COLLECTIVELY, THE "UNITED STATES"), AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION, RELEASE OR DISTRIBUTION WOULD BE UNLAWFUL.

THE COMMUNICATION OF THIS ANNOUNCEMENT AND ANY OTHER DOCUMENTS OR MATERIALS RELATING TO THE RETAIL OFFER AS A FINANCIAL PROMOTION IS ONLY BEING MADE TO, AND MAY ONLY BE ACTED UPON BY, THOSE PERSONS IN THE UNITED KINGDOM FALLING WITHIN ARTICLE 43 OF THE FINANCIAL SERVICES AND MARKETS ACT 2000 (FINANCIAL PROMOTION) ORDER 2005, AS AMENDED (WHICH INCLUDES AN EXISTING MEMBER OF VERICI DX PLC). ANY INVESTMENT OR INVESTMENT ACTIVITY TO WHICH THIS ANNOUNCEMENT RELATES IS AVAILABLE ONLY TO SUCH PERSONS AND WILL BE ENGAGED IN ONLY WITH SUCH PERSONS.

THIS ANNOUNCEMENT SHOULD BE READ IN ITS ENTIRETY. IN PARTICULAR, THE INFORMATION IN THE "IMPORTANT NOTICES" SECTION OF THE ANNOUNCEMENT SHOULD BE READ AND UNDERSTOOD.

Capitalised terms used in this Announcement have the meaning given to them in the Retail Offer Launch Announcement (as defined below), unless otherwise defined in this Announcement.

14 February 2024

Verici Dx plc

("Verici" or the "Company")

Result of Retail Offer

 

Further to the announcement made by the Company on 25 January 2024 (RNS number: 9314A) (the "Retail Offer Launch Announcement"), Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, is pleased to announce that it has raised gross proceeds of £0.28 million pursuant to the Retail Offer which was oversubscribed. Overall, taking into account the £6.22 million raised via the Placing, the total gross proceeds of the Fundraising amount to £6.50 million. Subject to the Retail Offer becoming unconditional, a total of 3,111,111 new Ordinary Shares ("Retail Offer Shares") will be issued at 9.0 pence per Retail Offer Share ("Issue Price").

Consequently, and subject to the passing of certain resolutions (the "Resolutions"), which are required to implement the Fundraising, at the General Meeting, an application will be made to the London Stock Exchange for the admission of, in aggregate, 72,222,222 new Ordinary Shares (comprising 69,111,111 Placing Shares and 3,111,111 Retail Offer Shares) to trading on AIM. Admission and dealings in the new Ordinary Shares are expected to take place at 8.00 a.m. on 20 February 2024 ("Admission").

The Retail Offer is wholly conditional upon, inter alia, (i) the Resolutions being duly passed by the shareholders of the Company at the General Meeting to be held at 12 p.m. on 19 February 2024 at Shoosmiths LLP's office in London at No. 1 Bow Churchyard, London, EC4M 9DQ, (ii) admission of the Retail Offer Shares to trading on AIM and (iii) completion of the Placing and admission of the Placing Shares to trading on AIM.

The new Ordinary Shares, when issued, will be fully paid and will rank pari passu in all respects with the existing Ordinary Shares, including the right to receive all dividends and other distributions declared, made or paid after the date of issue.

Following Admission, the Company's enlarged issued ordinary share capital will be 242,541,467. This figure may be used by shareholders of the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Enquiries:

Verici Dx

www.vericidx.com

Sara Barrington, CEO 

Via IR-Connect

Julian Baines, Chairman

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Sam Butcher / Jalini Kalaravy

IR-Connect

www.ir-connect.co.uk

Lorraine Rees

investors@vericidx.com

 

IMPORTANT NOTICES 

The content of this Announcement has been prepared by, and is the sole responsibility of, the Company.

 

The Retail Offer is only open to investors in the United Kingdom who fall within Article 43 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (which includes an existing member of the Company).

 

This Announcement and the information contained herein is restricted and is not for publication, release or distribution, directly or indirectly, in whole or in part, in or into or from the United States (including its territories and possessions, any state of the United States and the District of Columbia (the "United States" or "US")), Australia, Canada, Japan, New Zealand, the Republic of South Africa or any other jurisdiction where to do so might constitute a violation of the relevant laws or regulations of such jurisdiction.

 

The Retail Offer Shares have not been and will not be registered under the US Securities Act of 1933, as amended (the "US Securities Act") or under the applicable state securities laws of the United States and may not be offered or sold directly or indirectly in or into the United States or to or for the account or benefit of any US person (within the meaning of Regulation S under the US Securities Act) (a "US Person"). No public offering of the Retail Offer Shares is being made in the United States. The Retail Offer Shares are being offered and sold outside the United States in "offshore transactions", as defined in, and in compliance with, Regulation S under the US Securities Act. In addition, the Company has not been, and will not be, registered under the US Investment Company Act of 1940, as amended.

 

This Announcement does not constitute an offer to sell or issue or a solicitation of an offer to buy or subscribe for Retail Offer Shares in the United States, Australia, Canada, Japan, New Zealand the Republic of South Africa or any other jurisdiction in which such offer or solicitation is or may be unlawful. No public offer of the securities referred to herein is being made in any such jurisdiction.

 

The distribution of this Announcement may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein comes should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

 

Singer Capital Markets Securities Limited ("Singer"), which is authorised and regulated in the United Kingdom by the FCA is acting exclusively for the Company and no-one else in connection with the transactions and arrangements described in this Announcement and will not regard any other person (whether or not a recipient of this Announcement) as a client in relation to the transactions and arrangements described in this Announcement. Singer is not responsible to anyone other than the Company for providing the protections afforded to clients of Singer or for providing advice in connection with the contents of this Announcement, or the transactions and arrangements described in this Announcement.

 

Singer Capital Markets Advisory LLP ("SCM Advisory"), which is authorised and regulated in the United Kingdom by the FCA, is acting as nominated adviser to the Company for the purposes of the AIM Rules and no-one else in connection with the transactions and arrangements described in this Announcement and will not be responsible to any other person (whether or not a recipient of this Announcement) as a client in relation to the transactions and arrangements described in this Announcement. SCM Advisory is not responsible to anyone, other than the Company, for providing the protections afforded to clients of SCM Advisory or for providing advice in connection with the contents of this Announcement or the transactions and arrangements described herein. SCM Advisory's responsibilities as the Company's nominated adviser under the AIM Rules for Nominated Advisers published by the London Stock Exchange plc are owed solely to the London Stock Exchange plc and are not owed to the Company or to any director or to any other person.

 

The value of Ordinary Shares and the income from them is not guaranteed and can fall as well as rise due to stock market movements. When you sell your investment, you may get back less than you originally invested. Figures refer to past performance and past performance is not a reliable indicator of future results. Returns may increase or decrease as a result of currency fluctuations.

 

Certain statements in this Announcement are forward-looking statements which are based on the Company's expectations, intentions and projections regarding its future performance, anticipated events or trends and other matters that are not historical facts. These forward-looking statements, which may use words such as "aim", "anticipate", "believe", "intend", "estimate", "expect" and words of similar meaning, include all matters that are not historical facts. These forward-looking statements involve risks, assumptions and uncertainties that could cause the actual results of operations, financial condition, liquidity and dividend policy and the development of the industries in which the Company's businesses operate to differ materially from the impression created by the forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Given those risks and uncertainties, prospective investors are cautioned not to place undue reliance on forward-looking statements.

 

These forward-looking statements speak only as at the date of this Announcement and cannot be relied upon as a guide to future performance. The Company and Singer expressly disclaim any obligation or undertaking to update or revise any forward-looking statements contained herein to reflect actual results or any change in the assumptions, conditions or circumstances on which any such statements are based unless required to do so by the FCA, London Stock Exchange plc or applicable law.

 

The information in this Announcement is for background purposes only and does not purport to be full or complete. None of Singer or any of their respective affiliates, accepts any responsibility or liability whatsoever for, or makes any representation or warranty, express or implied, as to this Announcement, including the truth, accuracy or completeness of the information in this Announcement (or whether any information has been omitted from the Announcement) or any other information relating to the Company or associated companies, whether written, oral or in a visual or electronic form, and howsoever transmitted or made available or for any loss howsoever arising from any use of the Announcement or its contents or otherwise arising in connection therewith. Singer and its affiliates, accordingly disclaim all and any liability whether arising in tort, contract or otherwise which they might otherwise be found to have in respect of this Announcement or its contents or otherwise arising in connection therewith.

 

Any indication in this Announcement of the price at which the Ordinary Share have been bought or sold in the past cannot be relied upon as a guide to future performance. Persons needing advice should consult an independent financial adviser. No statement in this Announcement is intended to be a profit forecast and no statement in this Announcement should be interpreted to mean that earnings or target dividend per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings or dividends per share of the Company.

 

Neither the content of the Company's website (or any other website) nor the content of any website accessible from hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this Announcement. The Retail Offer Shares to be issued or sold pursuant to the Retail Offer will not be admitted to trading on any stock exchange other than the AIM market of London Stock Exchange plc.

 

Information to Distributors

 

UK Product Governance Requirements

 

Solely for the purposes of the product governance requirements of Chapter 3 of the FCA Handbook Product Intervention and Product Governance Sourcebook (the "UK MiFIR Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the UK MiFIR Product Governance Requirements) may otherwise have with respect thereto, the Retail Offer Shares have been subject to a product approval process, which has determined that the Retail Offer Shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in paragraphs 3.5 and 3.6 of COBS; and (ii) eligible for distribution through all permitted distribution channels (the "Target Market Assessment"). Notwithstanding the Target Market Assessment, distributors should note that: the price of the Retail Offer Shares may decline and investors could lose all or part of their investment; the Retail Offer Shares offer no guaranteed income and no capital protection; and an investment in the Retail Offer Shares is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to any contractual, legal or regulatory selling restrictions in relation to the Retail Offer.

 

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of Chapters 9A or 10A respectively of COBS; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the Retail Offer Shares. Each distributor is responsible for undertaking its own target market assessment in respect of the Retail Offer Shares and determining appropriate distribution channels.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
IOEBZLBFZLLFBBQ
Date   Source Headline
11th Oct 20247:00 amRNSUpdate on Local Coverage Determination and Trading
31st Jul 20247:00 amRNSLaunch of PTRA Assay using Verici Dx's technology
15th Jul 20247:00 amRNSHalf-year Report
11th Jul 20242:00 pmRNSNotice of Results and Business Update
1st Jul 20247:00 amRNSSignificant milestone re Thermo Fisher agreement
25th Jun 20241:27 pmRNSResult of AGM
18th Jun 20247:00 amRNSTransfer of urine samples to Thermo Fisher
31st May 20241:57 pmRNSNotice of AGM and posting of Annual Report
31st May 202410:00 amRNSLaunch of patient-focused educational tool
30th May 20247:00 amRNS2023 Annual Results
24th May 20247:00 amRNSNew data to be presented at ATC
27th Feb 20244:08 pmRNSHolding(s) in Company
22nd Feb 20247:00 amRNSHolding(s) in Company
21st Feb 20244:53 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSHolding(s) in Company
19th Feb 202412:35 pmRNSResult of General Meeting
14th Feb 20247:00 amRNSResult of Retail Offer
31st Jan 20247:00 amRNSVerici Dx announces new research initiative
26th Jan 202412:32 pmRNSPublication of Circular
25th Jan 202411:00 amRNSLaunch of Retail Offer
24th Jan 20246:11 pmRNSResult of Placing
24th Jan 202410:39 amRNSClose of Accelerated Bookbuild
24th Jan 20247:00 amRNSProposed Fundraising
8th Jan 20247:00 amRNSCAP accreditation
8th Jan 20247:00 amRNSMedicare National Payment Rate Confirmation
11th Dec 20237:00 amRNSTutiviaâ„¢ validation study published in Journal
29th Nov 20237:00 amRNSISO 27001 Information Security Certification
20th Nov 20237:00 amRNSInvestor Presentation
15th Nov 20237:00 amRNSCommercialisation agreement with Thermo Fisher
2nd Nov 20237:00 amRNSClaravaâ„¢ poster to be presented at ASN Kidney Week
29th Sep 20237:00 amRNSHalf-year Report
20th Jul 20237:00 amRNSCLIA Certificate of Compliance update
6th Jul 20237:00 amRNSInvestor Presentation
3rd Jul 20237:00 amRNSSuccessful clinical validation of Clarava™
29th Jun 20234:57 pmRNSResult of AGM
6th Jun 20237:00 amRNSNotice of AGM and posting of Annual Report
5th Jun 20237:01 amRNS2022 Annual Results
5th Jun 20237:00 amRNSProposed US pricing for Tutivia™
31st May 20237:00 amRNSNotice of Results
24th May 20237:01 amRNSUpdate re. EKF distribution of shares in Verici Dx
24th May 20237:00 amRNSDistribution of shares in Verici Dx plc
24th Apr 20237:00 amRNSFinal results timing
28th Mar 202311:05 amRNSSecond Price Monitoring Extn
28th Mar 202311:00 amRNSPrice Monitoring Extension
28th Mar 20239:05 amRNSSecond Price Monitoring Extn
28th Mar 20239:00 amRNSPrice Monitoring Extension
27th Mar 20234:35 pmRNSPrice Monitoring Extension
27th Mar 202311:05 amRNSSecond Price Monitoring Extn
27th Mar 202311:00 amRNSPrice Monitoring Extension
22nd Mar 20237:00 amRNSOperational Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Make Better Investment Decisions

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.